<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03035032</url>
  </required_header>
  <id_info>
    <org_study_id>7015-MA-3072</org_study_id>
    <nct_id>NCT03035032</nct_id>
  </id_info>
  <brief_title>A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients</brief_title>
  <official_title>A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Singapore Pte. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety, efficacy, and impact on quality of
      life (QoL) of ELIGARD® in hormone-dependent prostate cancer patients in Asia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2017</start_date>
  <completion_date type="Actual">November 19, 2019</completion_date>
  <primary_completion_date type="Actual">November 19, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of drug-related adverse events</measure>
    <time_frame>Up to Month 18</time_frame>
    <description>The safety analysis is based on the occurrence of ELIGARD related AEs and ELIGARD related SAEs, independent of investigator assessed causality, occurring during the study will be collected and summarized according to their severity and relationship to ELIGARD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with testosterone &lt; 20 ng/dL</measure>
    <time_frame>Up to Month 18</time_frame>
    <description>Testosterone level will be assessed for all participants at each scheduled visit, prior to administering ELIGARD®, and at the follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with testosterone 20-50 ng/dL</measure>
    <time_frame>Up to Month 18</time_frame>
    <description>Testosterone level will be assessed for all participants at each scheduled visit, prior to administering ELIGARD®, and at the follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with testosterone &gt; 50 ng/dL</measure>
    <time_frame>Up to Month 18</time_frame>
    <description>Testosterone level will be assessed for all participants at each scheduled visit, prior to administering ELIGARD®, and at the follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Prostate Specific Antigen (PSA) progression</measure>
    <time_frame>Up to Month 18</time_frame>
    <description>PSA progression as the date that a 25% or greater increase and an absolute increase of 2 ng/mL or more from the nadir is documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life assessed by EORTC QLQ-PR25</measure>
    <time_frame>Baseline and up to Month 18</time_frame>
    <description>EORTC QLQ-PR25: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life assessed by EQ5D-5L</measure>
    <time_frame>Baseline and up to Month 18</time_frame>
    <description>EQ5D-5L: EuroQol 5 Dimension 5 Level Health State Utility Index</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Leuprolide group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leuprolide will be administered for 18 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide</intervention_name>
    <description>Subcutaneous Injection</description>
    <arm_group_label>Leuprolide group</arm_group_label>
    <other_name>Leuprolide acetate</other_name>
    <other_name>Eligard</other_name>
    <other_name>Leuprorelin acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A patient for whom the physician has decided to initiate treatment with a Luteinizing
             Hormone Releasing Hormone (LHRH) agonist in standard clinical practice

          -  Biopsy-proven prostate adenocarcinoma

          -  Locally advanced prostate cancer with biochemical relapse radical prostatectomy and/or
             radiotherapy, OR hormonal treatment-naive advanced or metastatic prostate cancer
             patient who has not received chemotherapy and has no plans to undergo treatment with
             chemotherapy at study entry.

          -  Patient who indicates that once the study is completed, he expects having access to
             androgen deprivation therapy (ADT), either medical or surgical, within the local
             healthcare system (either through public/ private health insurance or out of pocket
             payment).

        Exclusion Criteria:

          -  Patient with castrate resistant prostate cancer

          -  Patient who previously underwent bilateral orchiectomy

          -  Patient who has received prior treatment with LHRH analogues

          -  Prior or concomitant treatment with systemic chemotherapy. A patient where there is a
             likelihood to receive systemic chemotherapy should not be enrolled

          -  Life expectancy of &lt; 1 year due to comorbidities

          -  Participation in another interventional clinical trial within one month prior to study
             entry or during the duration of the study

          -  Patient who plans to receive intermittent ADT at the time of study entry

          -  Patient receiving non-palliative radiotherapy within 3 months prior to study entry

          -  Patient receiving adjuvant ADT in combination with definitive radiotherapy

          -  Patient with metastatic hormonal treatment-naive prostate cancer, for whom
             chemo-hormonal treatment (combination of Docetaxel and ADT) is indicated.

          -  Patient with hypersensitivity to gonadotropin releasing hormone (GnRH), GnRH agonist
             analogs or any of the components of ELIGARD®

          -  Patient with any contraindication for ELIGARD® use based on local prescribing
             information
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site HK01001</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HK01002</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ID02001</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site MY03002</name>
      <address>
        <city>Batu Caves</city>
        <state>Selangor</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site MY03001</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PH04001</name>
      <address>
        <city>Makati City</city>
        <state>Metro Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PH04003</name>
      <address>
        <city>Manila</city>
        <state>Metro Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PH04002</name>
      <address>
        <city>San Juan</city>
        <state>Metro Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SG05001</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SG05002</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SG05003</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW06001</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW06002</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW06003</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TH07001</name>
      <address>
        <city>Muang</city>
        <state>Chiang Mai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TH07004</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkhla</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TH07003</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site VN08001</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site VN08002</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Indonesia</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 25, 2017</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leuprolide acetate</keyword>
  <keyword>Prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

